Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Frequently asked questions
What sector does Caris Life Sciences, Inc. Common Stock (CAI) operate in?
Caris Life Sciences, Inc. Common Stock belongs to the Industrials sector and operates in the Biotechnology industry.
What is Caris Life Sciences, Inc. Common Stock (CAI) current stock price?
As of the latest data, Caris Life Sciences, Inc. Common Stock stock price is $22.18, with a previous close of $22.26. Caris Life Sciences, Inc. Common Stock lost -$0.08 in the last trading session, representing a -0.36% loss.
What is Caris Life Sciences, Inc. Common Stock (CAI) current market capitalization?
Caris Life Sciences, Inc. Common Stock market cap is approximately 6.27 billion.
What is Caris Life Sciences, Inc. Common Stock (CAI) Earnings Per Share (EPS)?
The trailing EPS is -$3.36, and the forward EPS is $0.36.
What is Caris Life Sciences, Inc. Common Stock (CAI) EBITDA?
Caris Life Sciences, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 8.61 million.
Does Caris Life Sciences, Inc. Common Stock (CAI) pay dividends?
No. Caris Life Sciences, Inc. Common Stock does not pay a dividend.
How did Caris Life Sciences, Inc. Common Stock (CAI) perform in its most recent earnings report?
In the last report (June 30, 2026), Caris Life Sciences, Inc. Common Stock posted an EPS surprise of -5,300% and a revenue surprise of 10.77%.
What is Caris Life Sciences, Inc. Common Stock (CAI) beta (volatility) score?
Caris Life Sciences, Inc. Common Stock has a beta of 0.071, indicating lower volatility than the overall market.
